Connacht Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Connacht Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,152	Closed	-$1.19M	–	157
2022 Q3	$1.19M	Buy	19,152 +1,931	+11%	+$135K	0.84%	31
2022 Q2	$1.37M	Buy	17,221 +6,720	+64%	+$636K	0.58%	47
2022 Q1	$1.1M	Buy	+10,501	New	+$1.02M	0.57%	54

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Connacht Asset Management's HZNP Position: Q4 2022 in Review

Connacht Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 19,152 shares — an estimated $1.19M sold.

Connacht Asset Management first reported a position in HZNP in Q1 2022 and held it in 3 quarters. The position peaked at $1.37M in Q2 2022. 613 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Connacht Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Connacht Asset Management sold 19,152 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $1.19M.
Connacht Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 3 quarters.
Connacht Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.37M in Q2 2022.
613 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Connacht Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.